The crosstalk of intratumor bacteria and the tumor

Jiating Huang; Yuqin Mao; Lishun Wang

doi:10.3389/fcimb.2023.1273254

The crosstalk of intratumor bacteria and the tumor

Front Cell Infect Microbiol. 2024 Jan 3:13:1273254. doi: 10.3389/fcimb.2023.1273254. eCollection 2023.

Authors

Jiating Huang^#^{1

2}, Yuqin Mao^#^{1

2}, Lishun Wang^{1

2}

Affiliations

¹ Center for Traditional Chinese Medicine and Gut Microbiota, Minhang Hospital, Fudan University, Shanghai, China.
² Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, Shanghai, China.

^# Contributed equally.

Abstract

The in-depth studies reveal the interaction between the host and commensal microbiomes. Symbiotic bacteria influence in tumor initiation, progression, and response to treatment. Recently, intratumor bacteria have been a burgeoning research field. The tumor microenvironment is under vascular hyperplasia, aerobic glycolysis, hypoxia, and immunosuppression. It might be attractive for bacterial growth and proliferation. As a component of the tumor microenvironment, intratumor bacteria influence tumor growth and metastasis, as well as the efficacy of anti-tumor therapies. Therefore, understanding the intricate interplay of intratumoral bacteria and the host might contribute to better approaches to treat tumors. In this review, we summarize current evidence about roles of intratumor bacteria in tumor initiation and anti-tumor therapy, and what is remained to be solved in this field.

Keywords: bacteria; immune; intratumor; therapy; tumor.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Bacteria
Humans
Immunosuppression Therapy
Neoplasms*
Tumor Microenvironment

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants from the National Natural Science Foundation of China (82372626, 82303578, 81803601 and 81872245), Fundamental Research Funds for Shanghai Municipal Health Commission (20214Y0327, 20214Y0328, 20214Y0326 and 2022YQ052), Fundamental Research Funds for Minhang Hospital (2021MHJC01, 2021MHJC02, 2022MHBJ01 and 2023MHBJ01), Shanghai Sailing Program (Grant No. 23YF1438700).